X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-01 | ICVX | Simpson Adam K. | CEO | S - Sale+OE | $15.29 | -15,000 | 1,141,765 | -1% | -$229,386 | |||||
| D | 2023-01-04 | ICVX | Kanesa-Thasan Niranjan | Chief Medical Officer | S - Sale+OE | $15.70 | -106,373 | 223,980 | -32% | -$1,670,460 | |||||
| D | 2024-01-02 | ICVX | Simpson Adam K. | CEO | S - Sale+OE | $15.67 | -15,000 | 1,050,281 | -1% | -$235,088 | |||||
| DM | 2023-12-20 | ICVX | Simpson Adam K. | CEO | S - Sale+OE | $15.44 | -152,205 | 1,050,281 | -13% | -$2,350,789 | |||||
2023-12-20 | ICVX | Russo Thomas Joseph | CFO | S - Sale | $15.46 | -15,183 | 38,037 | -29% | -$234,720 | ||||||
2023-12-20 | ICVX | Kanesa-Thasan Niranjan | Chief Medical Officer | S - Sale | $15.46 | -11,884 | 223,980 | -5% | -$183,692 | ||||||
2023-12-20 | ICVX | Cearley Cassia | Chief Business Officer | S - Sale | $15.46 | -7,934 | 130,694 | -6% | -$122,637 | ||||||
2023-12-13 | ICVX | Cearley Cassia | Chief Business Officer | S - Sale | $16.01 | -8,759 | 131,200 | -6% | -$140,190 | ||||||
2023-07-31 | ICVX | Kanesa-Thasan Niranjan | Chief Medical Officer | S - Sale | $8.86 | -3,323 | 235,864 | -1% | -$29,447 | ||||||
2023-07-31 | ICVX | Simpson Adam K. | CEO | S - Sale | $8.86 | -11,788 | 1,033,570 | -1% | -$104,459 | ||||||
2023-07-31 | ICVX | Russo Thomas Joseph | CFO | S - Sale | $8.86 | -3,066 | 45,620 | -6% | -$27,169 | ||||||
2023-07-31 | ICVX | Cearley Cassia | Chief Business Officer | S - Sale | $8.86 | -1,888 | 139,959 | -1% | -$16,731 | ||||||
| D | 2023-07-03 | ICVX | Holtzman Douglas | Chief Scientific Officer | S - Sale+OE | $8.85 | -16,356 | 292,846 | -5% | -$144,743 | |||||
2023-05-23 | ICVX | Cearley Cassia | Chief Business Officer | S - Sale | $10.00 | -10,000 | 141,847 | -7% | -$100,000 | ||||||
| D | 2023-04-03 | ICVX | Holtzman Douglas | Chief Scientific Officer | S - Sale+OE | $6.09 | -20,443 | 292,846 | -7% | -$124,407 | |||||
2023-03-06 | ICVX | Cearley Cassia | Chief Business Officer | S - Sale | $7.75 | -5,000 | 151,847 | -3% | -$38,737 | ||||||
2023-02-13 | ICVX | Bekiroglu Elizabeth | GC, Corp. Sec. | S - Sale | $10.69 | -5,922 | 103,007 | -5% | -$63,322 | ||||||
2023-02-13 | ICVX | Simpson Adam K. | CEO | S - Sale | $10.69 | -7,506 | 1,034,681 | -1% | -$80,259 | ||||||
| M | 2023-02-13 | ICVX | Holtzman Douglas | Chief Scientific Officer | S - Sale | $10.33 | -4,871 | 292,846 | -2% | -$50,338 | |||||
2023-02-13 | ICVX | Russo Thomas Joseph | CFO | S - Sale | $10.69 | -1,902 | 48,686 | -4% | -$20,337 | ||||||
2023-02-13 | ICVX | Kanesa-Thasan Niranjan | Chief Medical Officer | S - Sale | $10.69 | -1,794 | 239,187 | -1% | -$19,183 | ||||||
2023-02-13 | ICVX | Cearley Cassia | Chief Business Officer | S - Sale | $10.69 | -1,660 | 156,847 | -1% | -$17,750 | ||||||
| D | 2022-12-21 | ICVX | Simpson Adam K. | CEO | S - Sale+OE | $8.96 | -66,764 | 1,029,114 | -6% | -$598,406 | |||||
2022-12-15 | ICVX | Holtzman Douglas | Chief Scientific Officer | S - Sale | $11.14 | -19,648 | 296,050 | -6% | -$218,963 | ||||||
2022-09-08 | ICVX | Bekiroglu Elizabeth | GC, Corp. Sec. | S - Sale | $4.87 | -1,813 | 108,929 | -2% | -$8,835 | ||||||
| M | 2022-07-29 | ICVX | Simpson Adam K. | CEO | S - Sale | $6.75 | -11,377 | 1,081,509 | -1% | -$76,795 | |||||
| M | 2022-07-29 | ICVX | Russo Thomas Joseph | CFO | S - Sale | $6.75 | -2,959 | 48,921 | -6% | -$19,973 | |||||
| M | 2022-07-29 | ICVX | Holtzman Douglas | Chief Scientific Officer | S - Sale | $6.67 | -10,375 | 315,698 | -3% | -$69,168 | |||||
| M | 2022-07-29 | ICVX | Richardson Charles E | SVP, Technical Operations | S - Sale | $6.75 | -2,218 | 165,168 | -1% | -$14,972 | |||||
| M | 2022-07-29 | ICVX | Kanesa-Thasan Niranjan | Chief Medical Officer | S - Sale | $6.75 | -3,245 | 239,314 | -1% | -$21,904 | |||||
| M | 2022-07-29 | ICVX | Cearley Cassia | Chief Business Officer | S - Sale | $6.75 | -1,812 | 131,738 | -1% | -$12,231 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |